PF PRISM CV Company Profile

✉ Email this page to a colleague

PF PRISM CV has sixteen approved drugs.

There are twenty-nine US patents protecting PF PRISM CV drugs.

There are six hundred and twelve patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	CAPSULE;ORAL	217729-002	Sep 26, 2023		RX	Yes	Yes	7,767,678*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	8,791,140	⤷ Try a Trial		Y		⤷ Try a Trial
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	CAPSULE;ORAL	217729-002	Sep 26, 2023		RX	Yes	Yes	RE42376*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-003	Oct 27, 2017		RX	Yes	No	7,919,625*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018		RX	Yes	Yes	RE41783	⤷ Try a Trial		Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	6,984,403	⤷ Try a Trial
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	7,887,844	⤷ Try a Trial
Pf Prism Cv	VFEND	voriconazole	INJECTABLE;INTRAVENOUS	021267-001	May 24, 2002	5,773,443	⤷ Try a Trial
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008	7,291,347	⤷ Try a Trial
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-003	Feb 23, 2004	5,212,155*PED	⤷ Try a Trial
Pf Prism Cv	VFEND	voriconazole	TABLET;ORAL	021266-002	May 24, 2002	5,364,938	⤷ Try a Trial
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018	7,842,699	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2008-09-12
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2010-10-08
➤ Subscribe	Injection	25 mg/mL, 1.8 mL vial	➤ Subscribe	2011-05-25
➤ Subscribe	Tablets	0.5 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Extended-release Tablets	25 mg	➤ Subscribe	2015-05-08
➤ Subscribe	Tablets	1 mg and 5 mg	➤ Subscribe	2018-02-23
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	50 mg and 200 mg	➤ Subscribe	2008-04-14
➤ Subscribe	For Injection	50 mg per vial	➤ Subscribe	2009-06-15
➤ Subscribe	Tablets	1 mg and 2 mg	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-release Tablets	50 mg and 100 mg	➤ Subscribe	2012-02-29
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100mg and 500mg	➤ Subscribe	2016-09-06

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
South Korea	20090127949	⤷ Try a Trial
Poland	378759	⤷ Try a Trial
European Patent Office	1466889	⤷ Try a Trial
Eurasian Patent Organization	200200120	⤷ Try a Trial
Australia	2006323027	⤷ Try a Trial
Poland	355907	⤷ Try a Trial
African Regional IP Organization (ARIPO)	1486	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1218348	CA 2013 00010	Denmark	⤷ Try a Trial
0648494	C300055	Netherlands	⤷ Try a Trial	PRODUCT NAME: SIROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; NATL. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: CH CH/55243 20000926
1786785	2013C/021	Belgium	⤷ Try a Trial	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER
0401747	25/2001	Austria	⤷ Try a Trial	PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926
1218348	122013000016	Germany	⤷ Try a Trial	PRODUCT NAME: AXITINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/12/777/001-006 20120903
1786785	PA2013005	Lithuania	⤷ Try a Trial	PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
1666481	2017C/032	Belgium	⤷ Try a Trial	PRODUCT NAME: TOFACITINIB; AUTHORISATION NUMBER AND DATE: EU/1/17/1178 20170324
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.